Journal of Pharmaceutical Policy and Practice最新文献

{"title":"Advancing early access policies for innovative cancer drugs: a scoping review and explorative analysis in the Italian setting.","authors":"Margherita d'Errico, Diana Giannarelli, Daniela d'Angela, Carmine Pinto, Barbara Polistena, Federico Spandonaro","doi":"10.1080/20523211.2024.2377697","DOIUrl":"10.1080/20523211.2024.2377697","url":null,"abstract":"<p><strong>Introduction: </strong>Considering the clinical impact of innovative cancer therapies, policy makers strive to balance timely access and thorough value-assessment. While some European countries promoted early access schemes, Italy does not yet display a consolidated strategy for innovative drugs or for medicines targeting pathologies with a high unmet need.</p><p><strong>Methods: </strong>To better understand the risks and opportunities of early access strategies that could be applied in the Italian setting, we performed a scoping review, searching the PubMed and Web of Science databases and interviewing two field experts. The review results were complemented with an exemplificative quantitative analysis for a subset of innovative oncology drugs, to assess the clinical and economic impact of the price and reimbursement negotiation.</p><p><strong>Results: </strong>Our study suggests that early access schemes developed in Germany and France, combining a free-pricing period, pay-back mechanism, and arbitration, could serve as a basis for developing a feasible strategy in Italy. The quantitative analysis indicated that timely access to innovative drugs could have potentially prevented many cancer progressions, associated with a significant healthcare expenditure.</p><p><strong>Conclusion: </strong>Albeit not allowing to express a conclusive assessment, this study proposes a potential early access strategy for Italy and highlights the need for opening a debate on the opportunities and risks of such schemes.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2377697"},"PeriodicalIF":3.3,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pharmacists' interventions after a Drug and Therapeutics Committee (DTC) establishment during the COVID-19 pandemic.","authors":"Amira B Kassem, Ahmad Z Al Meslamani, Dina H Elmaghraby, Yosr Magdy, Mohamed AbdElrahman, Ahmed M E Hamdan, Hebatallah Ahmed Mohamed Moustafa","doi":"10.1080/20523211.2024.2372040","DOIUrl":"10.1080/20523211.2024.2372040","url":null,"abstract":"<p><strong>Introduction: </strong>Healthcare systems in developing countries faced significant challenges during COVID-19, grappling with limited resources and staffing shortages. Assessment of the impact of pharmaceutical care expertise, particularly in critical care units during the pandemics, in developing countries remains poorly explored. The principal aim of our study was to assess the impact of the Drug and Therapeutics Committee (DTC), comprising clinical pharmacists, on the incidence, types, and severity of medication errors and associated costs in using COVID-19 medications, especially antibiotics.</p><p><strong>Methods: </strong>An interventional pre-post study was carried out at a public isolation hospital in Egypt over 6 months.</p><p><strong>Results: </strong>Out of 499 medication orders, 238 (47.7%) had medication errors, averaging 2.38 errors per patient. The most frequent were prescribing errors (44.9%), specifically incorrect drug choice (57.9%), excessive dosage (29.9%), treatment duplication (4.5%), inadequate dosage (4.5%), and overlooked indications (3.6%). Linezolid and Remdesivir were the most common medications associated with prescribing errors. Pharmacists intervened 315 times, primarily discontinuing medications, reducing doses, introducing new medications, and increasing doses. These actions led to statistically significant cost reductions (<i>p</i> < 0.05) and better clinical outcomes; improved oxygen saturation, decreased fever, stabilised respiratory rates, and normalised white blood cell counts. So, clinical pharmacist interventions made a notable clinical and economic difference (66.34% reduction of the expenses) in antibiotics usage specifically and other medications used in COVID-19 management during the pandemic.</p><p><strong>Conclusion: </strong>Crucially, educational initiatives targeting clinical pharmacists can foster judicious prescribing habits.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2372040"},"PeriodicalIF":3.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to childhood cancer medicines in South Africa: a health systems analysis of barriers and enablers.","authors":"Iris R Joosse, Hendrika A van den Ham, Aukje K Mantel-Teeuwisse, Velisha A Perumal-Pillay, Fatima Suleman","doi":"10.1080/20523211.2024.2372033","DOIUrl":"10.1080/20523211.2024.2372033","url":null,"abstract":"<p><strong>Background: </strong>We sought to identify what barriers and facilitators determine current perceived access to childhood cancer care in South Africa through in-depth interviews with stakeholders in South Africa's public and private sectors.</p><p><strong>Methods: </strong>Qualitative semi-structured interviews were conducted with 29 key health system stakeholders, including policy-makers and regulators, medical insurance scheme informants, medicine suppliers, healthcare providers and civil society stakeholders. Identified barriers and facilitators in access to medicines and broader care were structured according to the pharmaceutical value chain (PVC).</p><p><strong>Results: </strong>Barriers and facilitators were identified across all components of the PVC. Key barriers included (1) a lack of political commitment to childhood cancers, (2) discontinuation of essential chemotherapeutics, (3) incomplete insurance coverage for childhood cancers, (4) stock-outs of essential medicines, (5) the inability to access care, including travel to healthcare facilities and (6) low awareness on childhood cancers among primary healthcare (PHC) workers. Proposed priority interventions included pricing flexibilities, increased transparency and consistency in decision-making and healthcare spending, and improved training of PHC staff, nurses and pharmacists on childhood cancers.</p><p><strong>Conclusion: </strong>This first comprehensive study of determinants of access to medicines used in childhood cancer in South Africa provides context-specific evidence for targeted policy development.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2372033"},"PeriodicalIF":3.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriateness of gentamicin therapeutic drug monitoring at a Middle Eastern tertiary hospital setting: a retrospective evaluation and quality audit.","authors":"Fatima Khalifa Al-Sulaiti, Dania Alkhiyami, Eman Zeyad I Elmekaty, Ahmed Awaisu, Nadir Kheir, Ahmed El-Zubair, Hend Khalifa Al-Sulaiti","doi":"10.1080/20523211.2024.2375753","DOIUrl":"10.1080/20523211.2024.2375753","url":null,"abstract":"<p><strong>Introduction: </strong>The use of gentamicin in the treatment of infectious diseases requires frequent monitoring to attain the best treatment outcomes.</p><p><strong>Objective: </strong>This study aimed to evaluate the appropriateness of gentamicin therapeutic drug monitoring (TDM) at a tertiary care hospital in Qatar.</p><p><strong>Methods: </strong>A one-year quantitative retrospective chart review of all gentamicin TDM records was conducted. Evidence-based criteria were applied to evaluate the appropriateness of gentamicin TDM in terms of indication, sampling times, and post-analytical actions.</p><p><strong>Results: </strong>Out of 59 captured gentamicin TDM records, 58 gentamicin samples were eligible for evaluation. Overall, gentamicin TDM appropriateness was achieved in 50% (<i>n</i> = 29) of the evaluated records. However, 12% (<i>n</i> = 7) of gentamicin drug concentrations were below the assay quantification limits or were not sampled appropriately. Inappropriate post-analytical actions (22.4%, <i>n</i> = 13) and inappropriate sampling times (44.8%, <i>n</i> = 26) were recorded. Most of the gentamicin blood samples (<i>n</i> = 43; 74.2%) were taken appropriately at steady-state. Inappropriate sampling time relative to the last dose was captured in 31% (<i>n</i> = 18) of the cases. Although 27.6% (<i>n</i> = 16) of gentamicin concentrations were non-therapeutic, continuing gentamicin dosing without adjustment was the most frequent post-analytical action (69.8%, <i>n</i> = 37). Gentamicin dose regimen continuations, dose regimen decreases and dose regimen discontinuations were inappropriately applied in 27% (<i>n</i> = 10), 25% (<i>n</i> = 2) and 14% (<i>n</i> = 1) of the times, respectively.</p><p><strong>Conclusion: </strong>Suboptimal gentamicin TDM practices exist in relation to sampling time and post-analytical actions. Studies exploring setting-specific reasons behind inappropriate TDM practices and methods of its optimisation are needed.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2375753"},"PeriodicalIF":3.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Point prevalence survey of antibiotics use among hospitalised neonates and children in Saudi Arabia: findings and implications.","authors":"Hind M Alosaimi, Mohammed K Alshammari, Mohammad M Fetyani, Maha S Allehidan, Tahani J Almalki, Khansa H Hussain, Haifaa H Hussain, Mohammed D Althobaiti, Abrar S Alharbi, Atheer A Alharthi, Amosha A Al-Shammari, Zainab A Al Jamea, Rayed A Alamro, Ali Najmi","doi":"10.1080/20523211.2024.2371411","DOIUrl":"10.1080/20523211.2024.2371411","url":null,"abstract":"<p><strong>Background: </strong>Neonates and children are more susceptible to a variety of infections, leading to frequent antibiotic prescriptions. However, the inappropriate use of antibiotics leads to antibiotic resistance and higher mortality rates. Therefore, this study aimed to determine the prevalence of antibiotic use, and current antibiotic prescribing practices among neonates and children admitted in the selected hospitals of Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional study was conducted from September to November 2023 to assess the prevalence of antibiotic use, and the current antibiotic prescribing practices across six hospitals of Saudi Arabia.</p><p><strong>Results: </strong>The study included 499 children and neonates, with 94.6% receiving antibiotic prescriptions. The most frequently prescribed antibiotic class was third-generation cephalosporin (31.5%), with ceftriaxone being the most commonly prescribed antibiotic (15%). The majority of patients were prescribed one antibiotic (81.4%), and the intravenous route (96.4%) was the primary route for administration. The majority of patients were prescribed antibiotics empirically (69.7%), and community-acquired infections (64.2%) were the most common type of infection for antibiotic prescription. Similarly, sepsis (39.2%) was the most common indication for antibiotics, and the majority of prescribed antibiotics (61.7%) belonged to the 'Watch' category as per WHO AWaRe classification.</p><p><strong>Conclusion: </strong>Our study revealed excessive antibiotic consumption in neonates and children, therefore quality improvement programmes including antimicrobial stewardship programmes are urgently needed to address ongoing issues.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2371411"},"PeriodicalIF":3.3,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attitudes of community pharmacists towards extending their professional roles in Oman.","authors":"Hisham Amjad Abdul Razzak, Syed Azhar Syed Sulaiman, Amer Hayat Khan, Sabin Thomas","doi":"10.1080/20523211.2024.2367018","DOIUrl":"10.1080/20523211.2024.2367018","url":null,"abstract":"<p><strong>Background: </strong>Over the last few decades, the pharmacy profession has witnessed a substantial evolution accompanied by the developing role of community pharmacists (CPs). Evidence indicates that extending the role of CPs contributes to fostering public health outcomes. However, in many countries, their role is still underused. To extend the role of CPs in Oman, it is crucial to understand their perception and determine the influences.</p><p><strong>Aim: </strong>This study determines the willingness of CPs in Oman to extend their role and assess their perception towards barriers.</p><p><strong>Method: </strong>A cross-sectional study was conducted across Oman using an online self-administered survey targeting CPs working in the private sector.</p><p><strong>Result: </strong>Generally, respondents welcomed broadening their professional role. However, among the top perceived barriers were shortage of staff, insufficient training, lack of interconnection between CPs and physicians, and regulation constraints. Different socio-demographic characteristics of respondents showed a noticeable impact on their responses.</p><p><strong>Conclusion: </strong>CPs welcomed extending their role. However, several obstacles were raised that need to be tackled to enable CPs to advance their role.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2367018"},"PeriodicalIF":3.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring antimicrobial stewardship education and training support for community pharmacists in the United Kingdom.","authors":"Sandra J Martin, Sarah Chadwick, Mina Bakhit, Kevin J Frost, Gillian Hawksworth, Mamoon A Aldeyab","doi":"10.1080/20523211.2024.2365224","DOIUrl":"10.1080/20523211.2024.2365224","url":null,"abstract":"","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2365224"},"PeriodicalIF":3.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A study of pharmacists-joint total parenteral nutrition in haematopoietic cell transplantation in accord with diagnosis related groups: A retrospective clinical research.","authors":"Le Yang, Lu-Lu Qiu, Hui-Yi Lv, Miao Li","doi":"10.1080/20523211.2024.2361320","DOIUrl":"10.1080/20523211.2024.2361320","url":null,"abstract":"<p><strong>Background: </strong>Within Diagnosis Related Groups, based on service capability, efficiency, and quality safety assessment, clinical pharmacists contribute to promoting rational drug utilisation in healthcare institutions. However, a deficiency of pharmacist involvement has been observed in the total parenteral nutrition support to patients following haematopoietic cell transplantation (HCT) within DRGs.</p><p><strong>Methods: </strong>This study involved 146 patients who underwent HCT at the Department of Haematology, the Second Affiliated Hospital of Dalian Medical University, spanning from January 2020 to December 2022.</p><p><strong>Results: </strong>Patients were allocated equally, with 73 in the control group and 73 in the pharmacist-involved group: baseline characteristics showed no statistics significance, including age, body mass index, nutrition risk screening-2002 score, liver and kidney function, etc. Albumin levels, prealbumin levels were significantly improved after a 7-day TPN support (34.92 ± 4.24 vs 36.25 ± 3.65, <i>P</i> = 0.044; 251.30 ± 95.72 vs 284.73 ± 83.15, <i>P</i> = 0.026). The body weight was increased after a 7-day support and before discharge (58.77 ± 12.47 vs 63.82 ± 11.70, <i>P</i> = 0.013; 57.61 ± 11.85 vs 64.92 ± 11.71, <i>P</i> < 0.001). The length of hospital stay, costs and the rate of re-admissions were significantly shortened (51.10 ± 1.42 vs 46.41 ± 1.86, <i>P</i> = 0.048; 360,162.67 ± 91,831.34 vs 324,070.16 ± 112,315.51, <i>P = </i>0.035; 61.64% vs 43.84%, <i>P = </i>0.046).</p><p><strong>Conclusions: </strong>Pharmacist-joint TPN support enhances the service efficiency score of medical units, ensuring the fulfilment of orders and rational medication.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2361320"},"PeriodicalIF":3.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11207917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141457604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do newer drugs treat fewer diseases, controlling for time since launch? Evidence from France and the U.S.","authors":"Frank R Lichtenberg","doi":"10.1080/20523211.2024.2357604","DOIUrl":"10.1080/20523211.2024.2357604","url":null,"abstract":"<p><strong>Background: </strong>More recently approved drugs have significantly fewer indications than drugs approved many years ago. One possible reason for this may be that, controlling for the number of years since approval or launch, more recently approved drugs have fewer indications (e.g. at the time of launch). The role of precision and personalised medicine has increased, and the goal of precision medicine is to provide a more precise approach for the prevention, diagnosis and treatment of disease. Drugs that have fewer indications may be 'more precise' than drugs that have many indications.</p><p><strong>Methods: </strong>We use different kinds of data from two countries - France and the U.S. - to analyze the relationship across many drugs between the number of indications of a drug, the drug's vintage - i.e. the year in which the drug was first marketed or approved - and its age - the number of years it has been marketed.</p><p><strong>Results: </strong>All the evidence from both countries indicates that, controlling for drug age, more recently approved drugs tend to have fewer indications than drugs approved many years ago. In the U.S., a 10-year increase in vintage is associated with a 10.7% decline in the effective number of indications of all drugs, and a 19.4% decline in the effective number of indications of drugs approved after 1989. In France, the positive effect on the number of indications of the increase in drug age was more than offset by the negative effect of the increase in drug vintage.</p><p><strong>Conclusions: </strong>More recently approved drugs are less likely to be 'general-purpose technologies' (or even multi-purpose technologies) than older drugs. The relative importance of 'precision medicine' has increased in recent decades. Drugs that have fewer indications may be 'more precise' than drugs that have many indications.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2357604"},"PeriodicalIF":3.3,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11188943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision medicine in pharmacy: assessing pharmacogenomics competence among pharmacists and pharmacy students.","authors":"Mohanad Odeh, Lana Sbitan, Noor Alzraikat, Haneen Tanous, Tarik Al-Diery","doi":"10.1080/20523211.2024.2354879","DOIUrl":"10.1080/20523211.2024.2354879","url":null,"abstract":"<p><strong>Background: </strong>Pharmacogenomics, a key component of precision medicine, aims to improve healthcare outcomes. As pharmacists play a pivotal role in this evolving field, an assessment of their preparedness to apply pharmacogenomics is imperative.</p><p><strong>Methods: </strong>In this cross-sectional study, a validated questionnaire (Content Validity Ratio > 0.741, <i>p</i> < 0.05) that demonstrated reliability (Cronbach's alpha for all scales > 0.7) gathered data on demographics, knowledge, attitudes, barriers, and confidence in pharmacogenomics among pharmacists and pharmacy students in Jordan. Statistical analysis assessed associations and their strength within the collected data and variables.</p><p><strong>Results: </strong>This study included 514 pharmacists and pharmacy students. Knowledge scores were moderate and correlated with academic level and pharmacy school attended. Most participants were open to providing pharmacogenomics testing and interpretation through pharmacy services, but the majority demonstrated concerns about potential misinterpretation of test results and the resulting patients' anxiety. Students cited limited accessibility, while pharmacists identified the lack of standardised guidelines as the main roadblock.</p><p><strong>Conclusion: </strong>This study highlights the need for education to prepare pharmacists for their role in pharmacogenomics. Despite positive attitudes from pharmacists, addressing knowledge gaps, the low confidence in recommending pharmacogenomics tests, and concerns about implementation are essential.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"17 1","pages":"2354879"},"PeriodicalIF":4.2,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}